PRESS RELEASE
The company will publish its 2024 annual financial report on May 9, 2025
Paris, May 1stst 2025, 10 am this
Ab Science SA (Euronext – FR0010557264 – AB) announced today that it had postponed the publication of its 2024 annual financial report, initially scheduled for April 30, 2025, to give the listeners time to finish their audit work.
The company will publish its 2024 annual financial report at the latest on Friday, May 9, 2025, after trade.
About Ab Science
Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and marketing of kinase protein inhibitors (IPM), a targeted protein class whose action is the key to the signaling pathways in cells. Our programs only target diseases with unsatisfied medical needs, often fatal with short -term or rare survival or refractory to the previous treatment line.
AB Science has developed a portfolio owner of molecules and the main compound of society, Masitinib, has already been recorded in veterinary medicine and is developed in human medicine in oncology, neurological diseases, inflammatory diseases and viral diseases. The company has its registered office in Paris, in France, and registered on Euronext Paris (TICKER: AB).
Further information is available on the AB Science website: www.ab-science.com.
Prospective statements – AB Science
This press release contains prospective instructions. These statements are not historical facts. These declarations include projections and estimates as well as the hypotheses on which they are based, declarations based on projects, objectives, intentions and expectations concerning financial results, events, operations, future services, product development and their potential or future performance.
These prospective declarations can often be identified by the words “wait”, “anticipated”, “believe”, “intention”, “estimate” or “plan” as well as other similar terms. While AB Science believes that these prospective declarations are reasonable, investors are informed that these prospective declarations are subject to many risks and uncertainties which are difficult to predict and, generally out of control of the science of AB and which can involve that real results and events differ considerably from those expressed, induced or anticipated in information and states of perspective. These risks and uncertainty include uncertainties linked to the development of company products that may not succeed or to marketing authorizations granted by the competent authorities or, more generally, any factor that can affect the marketing capacity of the products developed by AB Science, as well as those developed or identified in public documents published by AB Science. AB Science declines any obligation or commitment to update information and prospective declarations, subject to applicable regulations, in particular articles 223-1 and following. of the general regulation AMF.
For more information, please contact:
AB Science
Financial communication and media relations
investors@ab-science.com
